Found 118 articles
Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance
Ironwood launches as GI-focused healthcare company following separation of Cyclerion Therapeutics on April 1, 2019
Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020
Ironwood Pharmaceuticals, Inc. announced an adjustment to the conversion rate applicable to its existing 2.25% Convertible Senior Notes due 2022, effective April 15, 2019.
Today, Cyclerion has been launched on the second floor of a 200,000-square-foot , 3-story space on Binney Street, in Cambridge.
Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that it has completed the tax-free spin-off of its soluble guanylate cyclase (sGC) business, Cyclerion Therapeutics, Inc. (Cyclerion).
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that the Form 10 Registration Statement filed by Cyclerion Therapeutics, Inc. (Cyclerion) has been declared effective by the U.S. Securities and Exchange Commission (SEC).
Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering
Proceeds to advance Cyclerion’s soluble guanylate cyclase (sGC) programs targeting breakthrough treatments for serious and orphan diseases
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a commercial biotechnology company, today provided an update on its fourth quarter and full year 2018 results and recent business activities.
Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation
Important step toward launching two independent, publicly-traded companies
1/25/2019Movers and Shakers is BioSpace's weekly roundup of leadership appointments and changes within the biopharma world. Included this week are Genentech, Editas, Sage, Sangamo, and more.
Ironwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following Separation
Board members bring diverse experience tailored to the distinct opportunities and strategies of each new company
Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials
Ironwood Pharmaceuticals (Nasdaq: IRWD) today announced the initiation of a Phase 1 study evaluating IW-6463 in healthy volunteers. IW-6463 is an orally administered central nervous system (CNS)-penetrant soluble guanylate cyclase (sGC) stimulator that is being developed for the treatment of serious and orphan CNS disorders.
Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C
Ironwood anticipates that it will launch the drug with its partner in China, AstraZeneca, in the second half of 2019.
After four years at AstraZeneca, Chief Medical Officer Sean Bohen will be leaving the company following an organizational shakeup at the U.K.-based pharma giant. Bohen joined AstraZeneca from Genentech in 2015 and also serves as head of global medicines development.
AstraZeneca has indicated it plans to lay off 210 people in Boulder and Longmont. The reason is the company is consolidating “the biologics manufacturing network in one large-scale drug substance facility” in Frederick, Maryland.
1/11/2019Biopharma companies strengthen the leadership teams during the annual J.P. Morgan Healthcare Conference.
Baselga resigned from Memorial Sloan Kettering following reports he failed to disclose his financial ties to various pharma companies in articles he published.
Dr. Shetzline will lead global product development for Ironwood following separation
Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that the Ironwood board of directors has appointed chief executive officers (CEOs) of the two companies, effective at the time of Ironwood’s planned separation which is on track to be completed in the first half of 2019.